Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 35
Filtrer
1.
Cell Mol Neurobiol ; 43(8): 4157-4172, 2023 Nov.
Article de Anglais | MEDLINE | ID: mdl-37689594

RÉSUMÉ

TRPV1 represents a non-selective transient receptor potential cation channel found not only in sensory neurons, but also in motor nerve endings and in skeletal muscle fibers. However, the role of TRPV1 in the functioning of the neuromuscular junction has not yet been fully established. In this study, the Levator Auris Longus muscle preparations were used to assess the effect of pharmacological activation of TRPV1 channels on neuromuscular transmission. The presence of TRPV1 channels in the nerve terminal and in the muscle fiber was confirmed by immunohistochemistry. It was verified by electrophysiology that the TRPV1 channel agonist capsaicin inhibits the acetylcholine release, and this effect was completely absent after preliminary application of the TRPV1 channel blocker SB 366791. Nerve stimulation revealed an increase of amplitude of isometric tetanic contractions upon application of capsaicin which was also eliminated after preliminary application of SB 366791. Similar data were obtained during direct muscle stimulation. Thus, pharmacological activation of TRPV1 channels affects the functioning of both the pre- and postsynaptic compartment of the neuromuscular junction. A moderate decrease in the amount of acetylcholine released from the motor nerve allows to maintain a reserve pool of the mediator to ensure a longer signal transmission process, and an increase in the force of muscle contraction, in its turn, also implies more effective physiological muscle activity in response to prolonged stimulation. This assumption is supported by the fact that when muscle was indirect stimulated with a fatigue protocol, muscle fatigue was attenuated in the presence of capsaicin.


Sujet(s)
Acétylcholine , Capsaïcine , Souris , Animaux , Capsaïcine/pharmacologie , Acétylcholine/pharmacologie , Jonction neuromusculaire , Muscles squelettiques , Canaux cationiques TRPV
2.
Int J Mol Sci ; 24(10)2023 May 19.
Article de Anglais | MEDLINE | ID: mdl-37240370

RÉSUMÉ

Amyotrophic lateral sclerosis (ALS) is manifested as skeletal muscle denervation, loss of motor neurons and finally severe respiratory failure. Mutations of RNA-binding protein FUS are one of the common genetic reasons of ALS accompanied by a 'dying back' type of degeneration. Using fluorescent approaches and microelectrode recordings, the early structural and functional alterations in diaphragm neuromuscular junctions (NMJs) were studied in mutant FUS mice at the pre-onset stage. Lipid peroxidation and decreased staining with a lipid raft marker were found in the mutant mice. Despite the preservation of the end-plate structure, immunolabeling revealed an increase in levels of presynaptic proteins, SNAP-25 and synapsin 1. The latter can restrain Ca2+-dependent synaptic vesicle mobilization. Indeed, neurotransmitter release upon intense nerve stimulation and its recovery after tetanus and compensatory synaptic vesicle endocytosis were markedly depressed in FUS mice. There was a trend to attenuation of axonal [Ca2+]in increase upon nerve stimulation at 20 Hz. However, no changes in neurotransmitter release and the intraterminal Ca2+ transient in response to low frequency stimulation or in quantal content and the synchrony of neurotransmitter release at low levels of external Ca2+ were detected. At a later stage, shrinking and fragmentation of end plates together with a decrease in presynaptic protein expression and disturbance of the neurotransmitter release timing occurred. Overall, suppression of synaptic vesicle exo-endocytosis upon intense activity probably due to alterations in membrane properties, synapsin 1 levels and Ca2+ kinetics could be an early sign of nascent NMJ pathology, which leads to neuromuscular contact disorganization.


Sujet(s)
Sclérose latérale amyotrophique , Animaux , Souris , Sclérose latérale amyotrophique/génétique , Protéine FUS de liaison à l'ARN/génétique , Synapsine/génétique , Synapsine/métabolisme , Jonction neuromusculaire/métabolisme , Agents neuromédiateurs/métabolisme
3.
J Vis Exp ; (178)2021 12 01.
Article de Anglais | MEDLINE | ID: mdl-34927611

RÉSUMÉ

Estimation of the presynaptic calcium level is a key task in studying synaptic transmission since calcium entry into the presynaptic cell triggers a cascade of events leading to neurotransmitter release. Moreover, changes in presynaptic calcium levels mediate the activity of many intracellular proteins and play an important role in synaptic plasticity. Studying calcium signaling is also important for finding ways to treat neurodegenerative diseases. The neuromuscular junction is a suitable model for studying synaptic plasticity, as it has only one type of neurotransmitter. This article describes the method for loading a calcium-sensitive dye through the cut nerve bundle into the mice's motor nerve endings. This method allows the estimation of all parameters related to intracellular calcium changes, such as basal calcium level and calcium transient. Since the influx of calcium from the cell exterior into the nerve terminals and its binding/unbinding to the calcium-sensitive dye occur within the range of a few milliseconds, a speedy imaging system is required to record these events. Indeed, high-speed cameras are commonly used for the registration of fast calcium changes, but they have low image resolution parameters. The protocol presented here for recording calcium transient allows extremely good spatial-temporal resolution provided by confocal microscopy.


Sujet(s)
Calcium , Jonction neuromusculaire , Animaux , Calcium/métabolisme , Signalisation calcique , Souris , Microscopie confocale , Jonction neuromusculaire/physiologie , Terminaisons présynaptiques/physiologie , Transmission synaptique
4.
Clin Case Rep ; 9(3): 1571-1576, 2021 Mar.
Article de Anglais | MEDLINE | ID: mdl-33768891

RÉSUMÉ

A comprehensive work-up, clinical correlation, and differential diagnosis are needed to determine if abnormal findings such us hydromyelia in ALS patients are causative or incidental in order to rule out other, more curable conditions that resemble ALS.

5.
Molecules ; 25(18)2020 Sep 12.
Article de Anglais | MEDLINE | ID: mdl-32932702

RÉSUMÉ

In this study, novel derivatives based on 6-methyluracil and condensed uracil were synthesized, namely, 2,4-quinazoline-2,4-dione with ω-(ortho-nitrilebenzylethylamino) alkyl chains at the N atoms of the pyrimidine ring. In this series of synthesized compounds, the polymethylene chains were varied from having tetra- to hexamethylene chains, and secondary NH, tertiary ethylamino, and quaternary ammonium groups were introduced into the chains. The molecular modeling of the compounds indicated that they could function as dual binding site acetylcholinesterase inhibitors, binding to both the peripheral anionic site and active site. The data from in vitro experiments show that the most active compounds exhibit affinity toward acetylcholinesterase within a nanomolar range, with selectivity for acetylcholinesterase over butyrylcholinesterase reaching four orders of magnitude. In vivo biological assays demonstrated the potency of these compounds in the treatment of memory impairment using an animal model of Alzheimer disease.


Sujet(s)
Acetylcholinesterase/composition chimique , Maladie d'Alzheimer/traitement médicamenteux , Butyrylcholine esterase/composition chimique , Anticholinestérasiques/pharmacologie , Troubles de la mémoire/traitement médicamenteux , Uracile/composition chimique , Composés d'ammonium/composition chimique , Animaux , Anions , Comportement animal , Sites de fixation , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Domaine catalytique , Modèles animaux de maladie humaine , Conception de médicament , Évaluation préclinique de médicament , Humains , Concentration inhibitrice 50 , Apprentissage du labyrinthe , Souris , Simulation de docking moléculaire , Scopolamine , Uracile/analogues et dérivés
6.
Cell Chem Biol ; 27(11): 1425-1433.e7, 2020 11 19.
Article de Anglais | MEDLINE | ID: mdl-32846115

RÉSUMÉ

Glycine receptors (GlyRs) are indispensable for maintaining excitatory/inhibitory balance in neuronal circuits that control reflexes and rhythmic motor behaviors. Here we have developed Glyght, a GlyR ligand controlled with light. It is selective over other Cys-loop receptors, is active in vivo, and displays an allosteric mechanism of action. The photomanipulation of glycinergic neurotransmission opens new avenues to understanding inhibitory circuits in intact animals and to developing drug-based phototherapies.


Sujet(s)
Composés azoïques/pharmacologie , Récepteur de la glycine/antagonistes et inhibiteurs , Animaux , Composés azoïques/synthèse chimique , Composés azoïques/composition chimique , Cellules cultivées , Cricetulus , Femelle , Ligands , Mâle , Souris , Souris de lignée ICR , Simulation de docking moléculaire , Structure moléculaire , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Processus photochimiques , Récepteur de la glycine/métabolisme , Transmission synaptique/effets des médicaments et des substances chimiques
7.
Int J Mol Sci ; 21(9)2020 May 02.
Article de Anglais | MEDLINE | ID: mdl-32370194

RÉSUMÉ

Atrial fibrillation (AF) is one of the most prevalent forms of arrhythmia that carries an increased risk of stroke which, in turn, is strongly associated with cognitive decline. The majority of dementia cases are caused by Alzheimer's disease (AD) with obscure pathogenesis. While the exact mechanisms are unknown, the role of inflammatory processes and infectious agents have recently been implicated in both AD and AF, suggesting a common link between these maladies. Here, we present the main shared pathways underlying arrhythmia and memory loss. The overlapping predictive biomarkers and emerging joint pharmacological approaches are also discussed.


Sujet(s)
Maladie d'Alzheimer/physiopathologie , Fibrillation auriculaire/physiopathologie , Dysfonctionnement cognitif/physiopathologie , Infections/physiopathologie , Inflammation/physiopathologie , Accident vasculaire cérébral/physiopathologie , Démence/physiopathologie , Humains , Modèles biologiques , Facteurs de risque
8.
Neuropharmacology ; 155: 131-141, 2019 09 01.
Article de Anglais | MEDLINE | ID: mdl-31132435

RÉSUMÉ

Profound synaptic dysfunction contributes to early loss of short-term memory in Alzheimer's disease. This study was set up to analyze possible neuroprotective effects of two dual binding site inhibitors of acetylcholinesterase (AChE), a new 6-methyluracil derivative, C-35, and the clinically used inhibitor donepezil. Crystal structure of the complex between human AChE and C-35 revealed tight contacts of ligand along the enzyme active site gorge. Molecular dynamics simulations indicated that the external flexible part of the ligand establishes multiple transient interactions with the enzyme peripheral anionic site. Thus, C-35 is a dual binding site inhibitor of AChE. In transgenic mice, expressing a chimeric mouse/human amyloid precursor protein and a human presenilin-1 mutant, C-35 (5 mg/kg, i.p) and donepezil (0.75 mg/kg, i.p) partially reversed synapse loss, decreased the number of amyloid plaques, and restored learning and memory. To separate temporal symptomatic therapeutic effects, associated with the increased lifetime of acetylcholine in the brain, from possible disease-modifying effect, an experimental protocol based on drug withdrawal from therapy was performed. When administration of C-35 and donepezil was terminated three weeks after the trial started, animals that were receiving C-35 showed a much better ability to learn than those who received vehicle or donepezil. Our results provide additional evidence that dual binding site inhibitors of AChE have Alzheimer's disease-modifying action.


Sujet(s)
Acetylcholinesterase/métabolisme , Maladie d'Alzheimer/diétothérapie , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/métabolisme , Anticholinestérasiques/métabolisme , Donépézil/métabolisme , Développement de médicament/tendances , Uracile/analogues et dérivés , Animaux , Sites de fixation/physiologie , Cellules CHO , Anticholinestérasiques/usage thérapeutique , Cricetinae , Cricetulus , Donépézil/usage thérapeutique , Humains , Souris , Souris transgéniques , Répartition aléatoire , Résultat thérapeutique , Uracile/composition chimique , Uracile/métabolisme , Uracile/usage thérapeutique
9.
J Alzheimers Dis ; 69(2): 443-453, 2019.
Article de Anglais | MEDLINE | ID: mdl-30958382

RÉSUMÉ

BACKGROUND/OBJECTIVE: Alzheimer's disease (AD) is a progressive incurable neurodegenerative disorder. Glial cell line-derived neurotrophic factor (GDNF) is a prominent regulator of brain tissue and has an impressive potential for use in AD therapy. While its metabolism is still not fully understood, delivering neuropeptides such as GDNF via umbilical cord blood mononuclear cells (UCBMCs) to the sites of neurodegeneration is a promising approach in the development of innovative therapeutic avenues. METHODS: UCBMCs were transduced with adenoviral vectors expressing GDNF and injected into AD transgenic mice. Various parameters including homing and survival of transplanted cells, expression of GDNF and synaptic proteins, as well as spatial memory were evaluated. RESULTS: UCBMCs were observed in the hippocampus and cortex several weeks after transplantation, and their long-term presence was associated with improved spatial memory. Post-synaptic density protein 95 (PSD-95) and synaptophysin levels in the hippocampus were also effectively restored following the procedure in AD mice. CONCLUSIONS: Our data indicate that gene-cell therapy with GDNF-overexpressing UCBMCs may produce long-lasting neuroprotection and stimulation of synaptogenesis. Such adenoviral constructs could potentially possess a high therapeutic potential for the treatment of AD.


Sujet(s)
Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/thérapie , Transplantation de cellules souches de sang du cordon/méthodes , Modèles animaux de maladie humaine , Facteur neurotrophique dérivé des cellules gliales/biosynthèse , Hippocampe/métabolisme , Mémoire spatiale/physiologie , Maladie d'Alzheimer/génétique , Animaux , Homologue-4 de la protéine Disks Large/biosynthèse , Homologue-4 de la protéine Disks Large/génétique , Femelle , Facteur neurotrophique dérivé des cellules gliales/génétique , Cellules HEK293 , Humains , Souris , Souris transgéniques , Grossesse , Synaptophysine/biosynthèse , Synaptophysine/génétique
10.
Front Mol Neurosci ; 11: 416, 2018.
Article de Anglais | MEDLINE | ID: mdl-30483054

RÉSUMÉ

Mammalian brainstem hypoglossal motoneurones (HMs) receive powerful synaptic glycinergic inputs and are involved in a variety of motor functions, including respiration, chewing, sucking, swallowing, and phonation. During the early postnatal development, subunit composition of chloride-permeable glycine receptors (GlyRs) changes leading to a decrease of "fetal" alpha2 and elevation of "adult" alpha1 GlyR subunits. It has been recently demonstrated that niflumic acid (NFA), a member of the fenamate class of non-steroidal anti-inflammatory drugs, is an efficient subunits-specific blocker of GlyRs. At a heterologous expression of different GlyR subunits it has been shown that blocking potency of NFA is more than one order higher for alpha2 GlyRs than for receptors formed by alpha1 subunit. To reveal the action of NFA on the synaptic activity we analyzed here the effects of NFA on the glycinergic inhibitory post-synaptic currents in the HMs from mouse brainstem slices. In the whole-cell patch clamp configuration, the amplitude and the frequency of glycinergic synaptic currents from two age groups have been analyzed: "neonate" (P2-P4) and "juvenile" (P7-P12). Addition of NFA in the presence of antagonists of glutamate and GABA receptors caused a decrease in the mean amplitude and frequency of synaptic events. The degree of the inhibition induced by NFA decreased with the postnatal development, being higher on the motoneurons from "neonate" brainstem slices in comparison with the "juvenile" age group. Analysis of the pair-pulse facilitation suggests the post-synaptic origin of NFA action. These observations provide evidence on the developmental changes in the inhibition by NFA of glycinergic synaptic transmission, which reflects increase in the alpha1 and decrease in the alpha2 GlyR subunits expression in synapses to hypoglossal motoneurons during the early stages of postnatal life.

11.
Mol Neurobiol ; 54(6): 4756-4763, 2017 08.
Article de Anglais | MEDLINE | ID: mdl-27495938

RÉSUMÉ

Current treatment options of chronic, progressive degenerative neuropsychiatric conditions offer only marginal efficacy, and there is no therapy which arrests or even reverses these diseases. Interest in genetic engineering and cell-based approaches have constantly been increasing, although most of them so far proved to be fruitless or at best provided very slight clinical benefit. In the light of the highly complex patho-mechanisms of these maladies, the failure of drugs aimed at targeting single molecules is not surprising. In order to improve their effectiveness, the role of a unique triple-combination gene therapy was investigated in this study. Intravenous injection of human umbilical cord blood mononuclear cell (hUCBMC) cotransduced with adenoviral vectors expressing vascular endothelial growth factor (VEGF), glial cell-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM) resulted in prominent increase of life span and performance in behavioral tests in amyotrophic lateral sclerosis (ALS). Expression of the recombinant genes in hUCBMCs was confirmed as soon as 5 days after transduction by RT-PCR, and cells were detectable for as long as 1 month after grafting in lumbar spinal cord by immunofluorescent staining. Xenotransplantation of cells into mice blood without any immunosuppression demonstrated a high level of hUCBMCs homing and survivability in the central nervous system (CNS), most conspicuously in the spinal cord, but not in the spleen or liver. This study confirms an increased addressed homing and notable survivability of triple-transfected cells in lumbar spinal cord, yielding a remarkably enhanced therapeutic potential of hUCBMCs overexpressing neurotrophic factors.


Sujet(s)
Sclérose latérale amyotrophique/génétique , Sclérose latérale amyotrophique/thérapie , Sang foetal/cytologie , Thérapie génétique , Sclérose latérale amyotrophique/anatomopathologie , Animaux , Comportement animal , Numération cellulaire , Technique d'immunofluorescence , Protéines à fluorescence verte/métabolisme , Humains , Agranulocytes/métabolisme , Vertèbres lombales/anatomopathologie , Souris transgéniques , Analyse de survie , Résultat thérapeutique
12.
J Alzheimers Dis ; 54(4): 1373-1383, 2016 10 18.
Article de Anglais | MEDLINE | ID: mdl-27589530

RÉSUMÉ

Alzheimer's disease (AD) is a devastating and progressive form of dementia that is typically associated with a build-up of amyloid-ß plaques and hyperphosphorylated and misfolded tau protein in the brain. Presently, there is no single test that confirms AD; therefore, a definitive diagnosis is only made after a comprehensive medical evaluation, which includes medical history, cognitive tests, and a neurological examination and/or brain imaging. Additionally, the protracted prodromal phase of the disease makes selection of control subjects for clinical trials challenging. In this study we have utilized a gene-expression array to screen blood and skin punch biopsy (fibroblasts, keratinocytes, and endothelial cells) for transcriptional differences that may lead to a greater understanding of AD as well as identify potential biomarkers. Our analysis identified 129 differentially expressed genes from blood of dementia cases when compared to healthy individuals, and four differentially expressed punch biopsy genes between AD subjects and controls. Additionally, we identified a set of genes in both tissue compartments that showed transcriptional variation in AD but were largely stable in controls. The translational products of these variable genes are involved in the maintenance of the Golgi structure, regulation of lipid metabolism, DNA repair, and chromatin remodeling. Our analysis potentially identifies specific genes in both tissue compartments that may ultimately lead to useful biomarkers and may provide new insight into the pathophysiology of AD.


Sujet(s)
Maladie d'Alzheimer/sang , Maladie d'Alzheimer/génétique , Cellules endothéliales/métabolisme , Fibroblastes/métabolisme , Kératinocytes/métabolisme , Lymphocytes/métabolisme , Sujet âgé , Maladie d'Alzheimer/diagnostic , Marqueurs biologiques/métabolisme , Femelle , Humains , Mâle , Projets pilotes , Transcription génétique/physiologie
13.
J Nerv Ment Dis ; 203(10): 781-5, 2015 Oct.
Article de Anglais | MEDLINE | ID: mdl-26348587

RÉSUMÉ

Chronic disorders such as hypertension and diabetes mellitus are often associated with depressive and anxiety symptoms, as well as cognitive decline. Once developed, psychological support is essential for improving the quality of life. This study is aimed at identifying impaired mental health in connection with these systemic metabolic disorders. A total of 34 patients were included in this cross-sectional study: 17 hypertensive individuals with a mean age of 59 ± 10 years, and 17 diabetic patients aged 54 ± 10 years. The following psychometric tests were used: Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and self-reporting questionnaire (SRQ-20). A large number of patients with high blood pressure or diabetes was associated with mental health problems (82% or 65%, respectively; p = 0.246). Affective disorder, especially moderate to severe depression, was seen mainly in diabetic patients (76%), whereas hypertensive individuals had higher prevalence of anxiety (64%). There was no cognitive impairment in this middle-aged population. This study shows a high proportion of depression and anxiety symptoms in patients with hypertension or diabetes mellitus, reinforcing the importance of psychiatric support for appropriate control of these metabolic disorders.


Sujet(s)
Diabète/psychologie , Hypertension artérielle/psychologie , Anxiété/épidémiologie , Anxiété/étiologie , Troubles de la cognition/épidémiologie , Troubles de la cognition/étiologie , Études transversales , Dépression/épidémiologie , Dépression/étiologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Tests neuropsychologiques , Échelles d'évaluation en psychiatrie
14.
ChemMedChem ; 10(11): 1863-74, 2015 Nov.
Article de Anglais | MEDLINE | ID: mdl-26412714

RÉSUMÉ

Novel 6-methyluracil derivatives with ω-(substituted benzylethylamino)alkyl chains at the nitrogen atoms of the pyrimidine ring were designed and synthesized. The numbers of methylene groups in the alkyl chains were varied along with the electron-withdrawing substituents on the benzyl rings. The compounds are mixed-type reversible inhibitors of cholinesterases, and some of them show remarkable selectivity for human acetylcholinesterase (hAChE), with inhibitory potency in the nanomolar range, more than 10,000-fold higher than that for human butyrylcholinesterase (hBuChE). Molecular modeling studies indicate that these compounds are bifunctional AChE inhibitors, spanning the enzyme active site gorge and binding to its peripheral anionic site (PAS). In vivo experiments show that the 6-methyluracil derivatives are able to penetrate the blood-brain barrier (BBB), inhibiting brain-tissue AChE. The most potent AChE inhibitor, 3 d (1,3-bis[5-(o-nitrobenzylethylamino)pentyl]-6-methyluracil), was found to improve working memory in scopolamine and transgenic APP/PS1 murine models of Alzheimer's disease, and to significantly decrease the number and area of ß-amyloid peptide plaques in the brain.


Sujet(s)
Acetylcholinesterase/métabolisme , Maladie d'Alzheimer/traitement médicamenteux , Anticholinestérasiques/pharmacologie , Uracile/analogues et dérivés , Maladie d'Alzheimer/enzymologie , Animaux , Comportement animal/effets des médicaments et des substances chimiques , Encéphale/enzymologie , Anticholinestérasiques/synthèse chimique , Anticholinestérasiques/composition chimique , Cristallographie aux rayons X , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Humains , Souris , Souris transgéniques , Modèles moléculaires , Structure moléculaire , Relation structure-activité , Uracile/synthèse chimique , Uracile/composition chimique , Uracile/pharmacologie
15.
Diab Vasc Dis Res ; 12(6): 445-54, 2015 Nov.
Article de Anglais | MEDLINE | ID: mdl-26410835

RÉSUMÉ

Mental illnesses are frequent co-morbid conditions in chronic systemic diseases. High incidences of depression, anxiety and cognitive impairment complicate cardiovascular and metabolic disorders such as hypertension and diabetes mellitus. Lifestyle changes including regular exercise have been advocated to reduce blood pressure and improve glycaemic control. The purpose of this project was to evaluate the effect of physical training on the most prevalent corollary psychiatric problems in patients with chronic organic ailments. This longitudinal study assessed the mental health of hypertensive (age: 57 ± 8 years) and/or diabetic (age: 53 ± 8 years) patients using mini-mental state examination, Beck's depression inventory, Beck's anxiety inventory and self-reporting questionnaire-20 before and after a 3-month supervised resistance and aerobic exercise programme comprising structured physical activity three times a week. Clinically relevant improvement was observed in the Beck's depression inventory and Beck's anxiety inventory scores following the 12-week training (61%, p = 0.001, and 53%, p = 0.02, respectively). Even though statistically not significant (p = 0.398), the cognitive performance of this relatively young patient population also benefited from the programme. These results demonstrate positive effects of active lifestyle on non-psychotic mental disorders in patients with chronic systemic diseases, recommending exercise as an alternative treatment option.


Sujet(s)
Troubles anxieux/thérapie , Anxiété/thérapie , Cognition/physiologie , Exercice physique/physiologie , Mode de vie , Adulte , Sujet âgé , Anxiété/diagnostic , Anxiété/physiopathologie , Troubles anxieux/physiopathologie , Maladie chronique , Femelle , Humains , Études longitudinales , Mâle , Adulte d'âge moyen , Enquêtes et questionnaires
16.
Curr Gene Ther ; 15(3): 266-76, 2015.
Article de Anglais | MEDLINE | ID: mdl-25619885

RÉSUMÉ

Amyotrophic lateral sclerosis (ALS) is an incurable, chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons and paralysis of skeletal muscles. Reactivating dysfunctional areas is under earnest investigation utilizing various approaches. Here we present an innovative gene-cell construct aimed at reviving inert structure and function. Human umbilical cord blood cells (hUCBCs) transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were transplanted into transgenic ALS mice models. Significant improvement in behavioral performance (open-field and grip-strength tests), as well as increased life-span was observed in rodents treated with NCAM-VEGF or NCAM-GDNF co-transfected cells. Active trans-gene expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-cell therapy model yielded prominent symptomatic control and prolonged life-time in ALS. Incredible survivability of xeno-transpanted cells was also observed without any immune-suppression. These results suggest that engineered hUCBCs may offer effective gene-cell therapy in ALS.


Sujet(s)
Sclérose latérale amyotrophique/thérapie , Transplantation cellulaire , Dependovirus/génétique , Sang foetal/cytologie , Vecteurs génétiques , Facteur neurotrophique dérivé des cellules gliales/génétique , Espérance de vie , Molécules d'adhérence cellulaire neurales/génétique , Facteur de croissance endothéliale vasculaire de type A/génétique , Sclérose latérale amyotrophique/physiopathologie , Animaux , Femelle , Thérapie génétique/méthodes , Cellules HEK293 , Humains , Mâle , Souris , Souris transgéniques
17.
Neurochem Int ; 64: 24-8, 2014 Jan.
Article de Anglais | MEDLINE | ID: mdl-24211710

RÉSUMÉ

Alzheimer's disease (AD) is characterized by memory decline, but is often associated with non-cognitive symptoms, including muscular dysfunction. In the majority of cases these motor disturbances are seen when other neuro-degenerative disorders such as Parkinson's disease overlap dementia, however these can also be directly related to AD itself. Although the patho-mechanism remains largely unclear, ß-amyloid peptide (ßAP) is thought to be a key role-player in both the brain and periphery. Here we studied the electro-genesis of skeletal muscle fibers in a mouse transgenic AD model. Membrane potential was recorded by standard electro-physiological techniques. Compared to wild-type rodents, AD mice show severe disturbances in skeletal muscle electro-genesis manifested by significant depolarization of myo-fibers. These changes are not affected by short-term ßAP treatment, the mark of a chronic degenerative process in the periphery directly related to AD whereby ion pumps on muscle membranes exhibit reduced activity. This phenomenon may explain ionic imbalance and cellular dysfunction both in the neuro-muscular system and in the brain. The observed motor disturbances might play a key role in impaired activities of daily living, and addressing the muscular patho-physiology could improve quality of life in AD.


Sujet(s)
Maladie d'Alzheimer/métabolisme , Peptides bêta-amyloïdes/métabolisme , Mémoire/physiologie , Fibres musculaires squelettiques/métabolisme , Maladie d'Alzheimer/physiopathologie , Précurseur de la protéine bêta-amyloïde/métabolisme , Animaux , Modèles animaux de maladie humaine , Humains , Potentiels de membrane/physiologie , Souris , Souris transgéniques
18.
J Neuroimmunol ; 251(1-2): 73-9, 2012 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-22766135

RÉSUMÉ

Alzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinergic failure, but other neuro-transmitters are also deficient especially at late stages of the disease. Misfolded ß-amyloid peptide has been identified as a causative agent, however inflammatory changes also play a pivotal role. Even though the most prominent pathology is seen in the cognitive functions, specific abnormalities of the central nervous system (CNS) are also reflected in the periphery, particularly in the immune responses of the body. The aim of this study was to characterize the dopaminergic and serotonergic systems in AD, which are also markedly disrupted along with the hallmark acetyl-choline dysfunction. Peripheral blood mono-nuclear cells (PBMCs) from demented patients were judged against comparison groups including individuals with late-onset depression (LOD), as well as non-demented and non-depressed subjects. Cellular sub-populations were evaluated by mono-clonal antibodies against various cell surface receptors: CD4/CD8 (T-lymphocytes), CD19 (B-lymphocytes), CD14 (monocytes), and CD56 (natural-killer (NK)-cells). The expressions of dopamine D(3) and D(4), as well as serotonin 5-HT(1A), 5-HT(2A), 5-HT(2B) and 5-HT(2C) were also assessed. There were no significant differences among the study groups with respect to the frequency of the cellular sub-types, however a unique profound increase in 5-HT(2C) receptor exclusively in NK-cells was observed in AD. The disease-specific expression of 5-HT(2C), as well as the NK-cell cyto-toxicity, has been linked with cognitive derangement in dementia. These changes not only corroborate the existence of bi-directional communication between the immune system and the CNS, but also elucidate the role of inflammatory activity in AD pathology, and may serve as potential biomarkers for less invasive and early diagnostic purposes as well.


Sujet(s)
Maladie d'Alzheimer/métabolisme , Cellules tueuses naturelles/métabolisme , Récepteur de la sérotonine de type 5-HT2C/biosynthèse , Sujet âgé , Sujet âgé de 80 ans ou plus , Lymphocytes B/métabolisme , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD8+/métabolisme , Dépression/métabolisme , Femelle , Humains , Agranulocytes/métabolisme , Mâle , Récepteur D3 de la dopamine/biosynthèse , Récepteur D4 de la dopamine/biosynthèse , Récepteurs sérotoninergiques/biosynthèse
19.
Mol Cell Neurosci ; 49(1): 77-84, 2012 Jan.
Article de Anglais | MEDLINE | ID: mdl-21971579

RÉSUMÉ

OBJECTIVES: Among several other factors, the neuro-toxic ß-amyloid peptide (ßAP)-induced inflammatory mechanisms have also been implicated in the pathogenesis of Alzheimer's dementia (AD). Cytokines have recently emerged as prime candidates underlying this immune reaction. The purpose of this study was to evaluate the inflammatory response of peripheral blood mono-nuclear cells (PBMC) in AD. DESIGN: Cross-sectional (observational) study. SETTING: Behavioral and cognitive neurology clinic of the Universidade Federal de Minas Gerais in Belo Horizonte, Brazil. PARTICIPANTS: AD patients (n=19), healthy elderly (n=19) and young (n=14) individuals. MEASUREMENTS: Cytokine levels were assessed by enzyme-linked immuno-sorbent assay (ELISA) after exposing cells to a broad range of ßAP concentrations (10(-4)-10(-10)M) as a stimulus. AD samples were weighed against leukocytes harvested from non-demented young and elderly subjects. RESULTS: Cytokine production of PBMCs in the youth was characterized by low baseline levels when compared to cells from the older generation. In the aging population, AD cells were distinguished from the healthy elderly sub-group by an even higher basal cytokine secretion. The low resting concentration in young individuals was markedly increased after treatment with ßAP, however cells from the elderly, irrespective of their disease status, showed unchanged cytokine release following ßAP administration. Non-specific activation of PBMCs with anti-CD3/CD28 antibodies resulted in elevated interleukin (IL)-1ß concentrations in AD. CONCLUSIONS: These results demonstrate a general over-production of cytokines and resistance to ßAP in the old comparison group, with a more pronounced disruption/boosted pattern in AD. Our findings are in line with the hypothesis of "inflammaging", i.e. an enhanced inflammatory profile with normal aging and a further perturbed environment in AD. The observed cytokine profiles may serve as diagnostic biomarkers in dementia.


Sujet(s)
Maladie d'Alzheimer/immunologie , Peptides bêta-amyloïdes/pharmacologie , Cytokines/biosynthèse , Agranulocytes/immunologie , Adulte , Sujet âgé , Test ELISA , Femelle , Humains , Inflammation/immunologie , Mâle , Adulte d'âge moyen
20.
Muscle Nerve ; 43(6): 872-7, 2011 Jun.
Article de Anglais | MEDLINE | ID: mdl-21488058

RÉSUMÉ

INTRODUCTION: Alzheimer's ß-amyloid peptide (ßAP) is known to possess a wide range of toxic effects on neurons in vitro and in vivo; however, there is little information available regarding its impact on other excitable tissues such as skeletal muscles, which, apart from brain cells, are thought to also be targets of ßAP. METHODS: Utilizing the combination of electrophysiology and myography, we investigated whether ßAP also impairs the functioning of myocytes in frogs and mice. RESULTS: Although application of ßAP in the range of 10(-6) to 10(-8) M induced depolarization of muscle fibers in both species, it impaired contractility in frogs but not in mice, by reducing endplate potential amplitude and increasing the threshold potential. CONCLUSIONS: Unchanged contractility in the mouse in the presence of ßAP is due to a higher safety factor of neuromuscular transmission in mammals compared with amphibians. Possible clinical implications are discussed.


Sujet(s)
Peptides bêta-amyloïdes/toxicité , Encéphale/physiopathologie , Fibres musculaires squelettiques/physiologie , Muscles squelettiques/physiopathologie , Fragments peptidiques/toxicité , Peptides bêta-amyloïdes/physiologie , Animaux , Encéphale/métabolisme , Encéphale/anatomopathologie , Muscle diaphragme/métabolisme , Muscle diaphragme/physiopathologie , Électromyographie/méthodes , Souris , Fibres musculaires squelettiques/métabolisme , Fibres musculaires squelettiques/anatomopathologie , Muscles squelettiques/métabolisme , Neurones/métabolisme , Neurones/anatomopathologie , Neurones/physiologie , Fragments peptidiques/physiologie , Rana ridibunda , Spécificité d'espèce
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...